elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Cystic fibrosis
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Cystic fibrosis
RIS
0.001
(Research Intensity Score)
Papers
111
Top papers
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
2019 · 2146 citations
Cystic fibrosis
2021 · 661 citations
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
2021 · 387 citations
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
2019 · 1386 citations
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment
2025 · 32 citations
PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study
2024 · 41 citations
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
2018 · 731 citations
European Consensus on Malabsorption—UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption
2025 · 20 citations
The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges
2025 · 19 citations
Newest papers
Impact of CFTR modulator concentrations on clinical response in cystic fibrosis
2026 · 4 citations
Within-Person Sweat Chloride Variability in People with Cystic Fibrosis Measured via Wearable Microfluidic Sticker
2026
Automated Ultrashort Echo Time ( UTE ) MRI Low Signal Volume Analysis in Stable Pediatric Cystic Fibrosis and After Elexacaftor/Tezacaftor/Ivacaftor Therapy
2026 · 1 citations
Developmental dynamics of ovine lung in health and cystic fibrosis at single-cell resolution
2026
Pathogenetic therapy with ivacaftor + tezacaftor + elexacaftor plus ivacaftor: Assessment of efficacy and safety of switching within a single INN in children with cystic fibrosis in the Yaroslavl and Tula regions
2026
Resolution of recurrent pancreatitis and nutritional recovery with CFTR modulator therapy in CFTR-related disorder: a case report
2026
Zinc Starvation Drives Respiratory Remodeling and Metabolic Adaptations Associated with Cystic Fibrosis in Pseudomonas aeruginosa
2026
Novel therapeutics and diagnostics in mono- and polymicrobial biofilm infections: Addressing emerging challenges
2026
Long-term safety and efficacy of Lumacaftor/Ivacaftor in children 12 months of age and older with cystic fibrosis: a 96-week open-label study
2026
Browse all papers →
Cystic fibrosis's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Cystic fibrosis's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link